CoChat

Gut microbiota-derived propionate mediates the neuroprotective effect of osteocalcin in a mouse model of Parkinson’s disease

Open access

The DOI matches its Crossref record; the references it cites are not checked yet.

Abstract

Background: Parkinson’s disease (PD) is a neurodegenerative disorder with no absolute cure. The evidence of the involvement of gut microbiota in PD pathogenesis suggests the need to identify certain molecule(s) derived from the gut microbiota, which has the potential to manage PD. Osteocalcin (OCN), an osteoblast-secreted protein, has been shown to modulate brain function. Thus, it is of interest to investigate whether OCN could exert protective effect on PD and, if yes, whether the underlying mechanism lies in the subsequent changes in gut microbiota. Results: The intraperitoneal injection of OCN can effectively ameliorate the motor deficits and dopaminergic neuronal loss in a 6-hydroxydopamine-induced PD mouse model. The further antibiotics treatment and fecal microbiota transplantation experiments confirmed that the gut microbiota was required for OCN-induced protection in PD mice. OCN elevated Bacteroidetes and depleted Firmicutes phyla in the gut microbiota of PD mice with elevated potential of microbial propionate production and was confirmed by fecal propionate levels. Two months of orally administered propionate successfully rescued motor deficits and dopaminergic neuronal loss in PD mice. Furthermore, AR420626, the agonist of FFAR3, which is the receptor of propionate, mimicked the neuroprotective effects of propionate and the ablation of enteric neurons blocked the prevention of dopaminergic neuronal loss by propionate in PD mice. Conclusions: Together, our results demonstrate that OCN ameliorates motor deficits and dopaminergic neuronal loss in PD mice, modulating gut microbiome and increasing propionate level might be an underlying mechanism responsible for the neuroprotective effects of OCN on PD, and the FFAR3, expressed in enteric nervous system, might be the main action site of propionate.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40168-020-00988-6

Cites

Statistics

Figures

Fig. 1 OCN administration prevented motor impairments and dopaminergic neuronal loss in 6-OHDA-induced PD mice. a The experimental design of OCN intervention in 6-OHDA-induced PD mice (6-OHDA was injected into the right striatum of the mice). b (Upper panel) Bar plots of performance in the behavioral tests, including the open field test, cylinder test and rotarod test. n = 6-12 per group. (Lower panel) Representative traces in the open field test. Blue point: starting position; red point: ending position. c (Left panel) Representative immunostaining showing TH-positive neurons in the SN. (Right panel) The average number of TH-positive neurons in the ST. n = 3 per group, 3 sections per mouse. d (Left panel) Representative immunostaining (upper) and western blotting (lower) showing TH-positive fibers and TH protein levels in the striatum. (Right panel) The quantitation of TH-positive fibers (upper) and TH protein levels (lower) in the striatum. Immunostaining: n = 3 per group, 3 sections per mouse; western blotting: n = 3 per group. LOCN = 4 μg/kg OCN, HOCN = 40 μg/kg OCN. The data represent the mean ± SEM, p < 0.05 was set as the threshold for significance by one-way ANOVA followed by post hoc comparisons using Tukey’s test for multiple groups’ comparisons, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
Fig. 1 OCN administration prevented motor impairments and dopaminergic neuronal loss in 6-OHDA-induced PD mice. a The experimental design of OCN intervention in 6-OHDA-induced PD mice (6-OHDA was injected into the right striatum of the mice). b (Upper panel) Bar plots of performance in the behavioral tests, including the open field test, cylinder test and rotarod test. n = 6-12 per group. (Lower panel) Representative traces in the open field test. Blue point: starting position; red point: ending position. c (Left panel) Representative immunostaining showing TH-positive neurons in the SN. (Right panel) The average number of TH-positive neurons in the ST. n = 3 per group, 3 sections per mouse. d (Left panel) Representative immunostaining (upper) and western blotting (lower) showing TH-positive fibers and TH protein levels in the striatum. (Right panel) The quantitation of TH-positive fibers (upper) and TH protein levels (lower) in the striatum. Immunostaining: n = 3 per group, 3 sections per mouse; western blotting: n = 3 per group. LOCN = 4 μg/kg OCN, HOCN = 40 μg/kg OCN. The data represent the mean ± SEM, p < 0.05 was set as the threshold for significance by one-way ANOVA followed by post hoc comparisons using Tukey’s test for multiple groups’ comparisons, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001CC BY · PubMed Central
Fig. 2 Antibiotic pretreatment (Abx) blocked the OCN-induced improvements of motor impairments and dopaminergic neuronal loss in 6-OHDA-induced PD mice. a The experimental design for antibiotic treatment and 4 μg/kg OCN administration in 6-OHDA-induced PD mice. b (Upper panel) Bar plots of performance in the behavioral tests including the open field test, cylinder test, and rotarod test. n = 11-14 per group. (Lower panel) Representative traces in the open field test. Blue point: starting position; red point: ending position. c (Left panel) Representative immunostaining showing TH-positive neurons in the SN. (Right panel) The average number of TH-positive neurons in the ST. n = 3 per group, 3 sections per mouse. d (Left panel) Representative immunostaining (upper) and western blotting (lower) showing TH-positive fibers and TH protein levels in the striatum. (Right panel) The quantitation of TH-positive fibers (upper) and TH protein levels (lower) in the striatum. Immunostaining: n = 3 per group, 3 sections per mouse; western blotting: n = 3 per group. The data represent the mean ± SEM, p < 0.05 was set as the threshold for significance by one-way ANOVA followed by post hoc comparisons using Tukey’s test for multiple groups’ comparisons, *p < 0.05, **p < 0.01, *** p < 0.001, ****p < 0.0001
Fig. 2 Antibiotic pretreatment (Abx) blocked the OCN-induced improvements of motor impairments and dopaminergic neuronal loss in 6-OHDA-induced PD mice. a The experimental design for antibiotic treatment and 4 μg/kg OCN administration in 6-OHDA-induced PD mice. b (Upper panel) Bar plots of performance in the behavioral tests including the open field test, cylinder test, and rotarod test. n = 11-14 per group. (Lower panel) Representative traces in the open field test. Blue point: starting position; red point: ending position. c (Left panel) Representative immunostaining showing TH-positive neurons in the SN. (Right panel) The average number of TH-positive neurons in the ST. n = 3 per group, 3 sections per mouse. d (Left panel) Representative immunostaining (upper) and western blotting (lower) showing TH-positive fibers and TH protein levels in the striatum. (Right panel) The quantitation of TH-positive fibers (upper) and TH protein levels (lower) in the striatum. Immunostaining: n = 3 per group, 3 sections per mouse; western blotting: n = 3 per group. The data represent the mean ± SEM, p < 0.05 was set as the threshold for significance by one-way ANOVA followed by post hoc comparisons using Tukey’s test for multiple groups’ comparisons, *p < 0.05, **p < 0.01, *** p < 0.001, ****p < 0.0001CC BY · PubMed Central
Fig. 3 PD-derived microbiota induced PD-like motor impairments in gut microbiota-depleted mice. a The experimental design for fecal microbiota transplantation. b Bar plots of performance in the behavioral tests including pole test, rotarod test, and open field test. n = 10 per group. c Representative traces in the open field test. Blue point: starting position; red point: ending position. The data represent the mean ± SEM, p < 0.05 was set as the threshold for significance by one-way ANOVA followed by post hoc comparisons using Tukey’s test for multiple groups’ comparisons, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
Fig. 3 PD-derived microbiota induced PD-like motor impairments in gut microbiota-depleted mice. a The experimental design for fecal microbiota transplantation. b Bar plots of performance in the behavioral tests including pole test, rotarod test, and open field test. n = 10 per group. c Representative traces in the open field test. Blue point: starting position; red point: ending position. The data represent the mean ± SEM, p < 0.05 was set as the threshold for significance by one-way ANOVA followed by post hoc comparisons using Tukey’s test for multiple groups’ comparisons, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001CC BY · PubMed Central
Fig. 4 OCN administration modulated gut microbiota dysbiosis in 6-OHDA-induced PD mice. a Principal coordinate analysis (PCoA) plot based on unweighted UniFrac distance. b Heatmap of the gut microbiota taxa showed different RAs in different groups. Color key represents the RAs. c Venn diagram of differential taxa comparisons between control versus 6-OHDA and 6-OHDA+OCN versus 6-OHDA group. d Bar plots of the RAs of p_Bacteroidetes and p_Firmicutes at the phylum level and of overlapping taxa at the family levels indicated in c. The dosage of OCN was 4 μg/kg. n = 7–12 per group, data represent the mean ± SEM, p < 0.05 was set as the threshold for significance by one-way ANOVA followed by post hoc comparisons using Tukey’s test for multiple groups’ comparisons, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
Fig. 4 OCN administration modulated gut microbiota dysbiosis in 6-OHDA-induced PD mice. a Principal coordinate analysis (PCoA) plot based on unweighted UniFrac distance. b Heatmap of the gut microbiota taxa showed different RAs in different groups. Color key represents the RAs. c Venn diagram of differential taxa comparisons between control versus 6-OHDA and 6-OHDA+OCN versus 6-OHDA group. d Bar plots of the RAs of p_Bacteroidetes and p_Firmicutes at the phylum level and of overlapping taxa at the family levels indicated in c. The dosage of OCN was 4 μg/kg. n = 7–12 per group, data represent the mean ± SEM, p < 0.05 was set as the threshold for significance by one-way ANOVA followed by post hoc comparisons using Tukey’s test for multiple groups’ comparisons, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001CC BY · PubMed Central
Fig. 5 OCN administration increased fecal propionate levels in 6-OHDA-induced PD mice. a (Left panel) Metabolic pathway for acetate, propionate, and butyrate synthesis and corresponding KOs and genes are displayed. (Right panel) Bar plots of the RAs of K01847, K00634, K00929, and K00074, n = 7–12 per group. b Bar plots of comparing the fecal levels of acetate, propionate, and butyrate among groups. Data represent the mean ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. c Heatmap shows correlations analysis between the fecal level of SCFAs and the RAs of f_S24-7, f_Rikenellaceae, f_Lachnospiraceae, and f_unclassified Clostridiales. Color key represents the correlation coefficients, *p < 0.05, +p < 0.01. OCN-enriched taxa were marked in red color; depleted taxa were marked in blue. d Plots of correlation analysis between the fecal level of propionate and motor function. X-axis represented the values of open field test, cylinder test, and rotarod test; Y-axis represented the fecal propionate levels. K00656: pflD, formate C-acetyltransferase; K13788: pta, phosphate acetyltransferase; K00925: ackA, acetate kinase; K00626: Thl, acetyl-CoA C-acetyltransferase; K00074: Hbd, 3-hydroxybutyryl-CoA dehydrogenase; K00634: ptb, phosphate butyryltransferase; K00929: buk, butyrate kinase; K01034: but, acetate CoA-transferase alpha subunit; K01899: Sucla1, succinyl-CoA synthetase alpha subunit; K01847: Mut, methylmalonyl-CoA mutase; K11264: mmcD, methylmalonyl-CoA decarboxylase; K13923: pduL, phosphate propanoyltransferase; K00932: tdcD, propionate kinase; K01905: acdA, acetate-CoA ligase (ADP-forming) subunit alpha. The dosage of OCN was 4 μg/kg
Fig. 5 OCN administration increased fecal propionate levels in 6-OHDA-induced PD mice. a (Left panel) Metabolic pathway for acetate, propionate, and butyrate synthesis and corresponding KOs and genes are displayed. (Right panel) Bar plots of the RAs of K01847, K00634, K00929, and K00074, n = 7–12 per group. b Bar plots of comparing the fecal levels of acetate, propionate, and butyrate among groups. Data represent the mean ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. c Heatmap shows correlations analysis between the fecal level of SCFAs and the RAs of f_S24-7, f_Rikenellaceae, f_Lachnospiraceae, and f_unclassified Clostridiales. Color key represents the correlation coefficients, *p < 0.05, +p < 0.01. OCN-enriched taxa were marked in red color; depleted taxa were marked in blue. d Plots of correlation analysis between the fecal level of propionate and motor function. X-axis represented the values of open field test, cylinder test, and rotarod test; Y-axis represented the fecal propionate levels. K00656: pflD, formate C-acetyltransferase; K13788: pta, phosphate acetyltransferase; K00925: ackA, acetate kinase; K00626: Thl, acetyl-CoA C-acetyltransferase; K00074: Hbd, 3-hydroxybutyryl-CoA dehydrogenase; K00634: ptb, phosphate butyryltransferase; K00929: buk, butyrate kinase; K01034: but, acetate CoA-transferase alpha subunit; K01899: Sucla1, succinyl-CoA synthetase alpha subunit; K01847: Mut, methylmalonyl-CoA mutase; K11264: mmcD, methylmalonyl-CoA decarboxylase; K13923: pduL, phosphate propanoyltransferase; K00932: tdcD, propionate kinase; K01905: acdA, acetate-CoA ligase (ADP-forming) subunit alpha. The dosage of OCN was 4 μg/kgCC BY · PubMed Central
Fig. 6 Oral administration of propionate prevented motor impairments and dopaminergic neuronal loss in 6-OHDA-induced PD mice. a (Upper panel) The experimental design for propionate intervention in PD mice. (Lower panel) Quantitative measurement by GC/MS showing the fecal and serum levels of propionate. n = 7–12 per group. b (Upper panel) Bar plots of performance in the behavioral tests, including the open field test, cylinder test, and rotarod test. n = 7–12 per group. (Lower panel) Representative traces in the open field test. Blue point: starting position; red point: ending position. c (Left panel) Representative immunostaining showing TH-positive neurons in the SN. (Right panel) The average number of TH-positive neurons in the ST. n = 3 per group, 3 sections per mouse. d (Left panel) Representative immunostaining (upper) and western blotting (lower) showing TH-positive fibers and TH protein levels in the striatum. (Right panel) The quantification of TH-positive fibers (upper) and TH protein levels (lower) in the striatum. Immunostaining: n = 3 per group, 3 sections per mouse; western blotting: n = 3 per group. The data represent the mean ± SEM, p < 0.05 was set as the threshold for significance by one-way ANOVA followed by post hoc comparisons using Tukey’s test for multiple groups’ comparisons, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
Fig. 6 Oral administration of propionate prevented motor impairments and dopaminergic neuronal loss in 6-OHDA-induced PD mice. a (Upper panel) The experimental design for propionate intervention in PD mice. (Lower panel) Quantitative measurement by GC/MS showing the fecal and serum levels of propionate. n = 7–12 per group. b (Upper panel) Bar plots of performance in the behavioral tests, including the open field test, cylinder test, and rotarod test. n = 7–12 per group. (Lower panel) Representative traces in the open field test. Blue point: starting position; red point: ending position. c (Left panel) Representative immunostaining showing TH-positive neurons in the SN. (Right panel) The average number of TH-positive neurons in the ST. n = 3 per group, 3 sections per mouse. d (Left panel) Representative immunostaining (upper) and western blotting (lower) showing TH-positive fibers and TH protein levels in the striatum. (Right panel) The quantification of TH-positive fibers (upper) and TH protein levels (lower) in the striatum. Immunostaining: n = 3 per group, 3 sections per mouse; western blotting: n = 3 per group. The data represent the mean ± SEM, p < 0.05 was set as the threshold for significance by one-way ANOVA followed by post hoc comparisons using Tukey’s test for multiple groups’ comparisons, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001CC BY · PubMed Central
Fig. 7 Intragastric administration of FFAR3 agonist prevented motor impairments and dopaminergic neuronal loss in 6-OHDA-induced PD mice. a The experimental design for FFAR3 agonist intervention in PD mice. b (Upper panel) Bar plots of performance in the behavioral tests, including the open field test, pole test, cylinder test, and rotarod test. n = 6 per group. (Lower panel) Representative traces in the open field test. Blue point: starting position; red point: ending position. c (Left panel) Representative immunostaining showing TH-positive neurons in the SN. (Right panel) The average number of TH-positive neurons in the ST. n = 3 per group, 3 sections per mouse. d (Left panel) Representative immunostaining (upper) and western blotting (lower) showing TH-positive fibers and TH protein levels in the striatum. (Right panel) The quantification of TH-positive fibers (upper) and TH protein levels (lower) in the striatum. Immunostaining: n = 3 per group, 3 sections per mouse; western blotting: n = 3 per group. The data represent the mean ± SEM, p < 0.05 was set as the threshold for significance by one-way ANOVA followed by post hoc comparisons using Tukey’s test for multiple groups’ comparisons, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
Fig. 7 Intragastric administration of FFAR3 agonist prevented motor impairments and dopaminergic neuronal loss in 6-OHDA-induced PD mice. a The experimental design for FFAR3 agonist intervention in PD mice. b (Upper panel) Bar plots of performance in the behavioral tests, including the open field test, pole test, cylinder test, and rotarod test. n = 6 per group. (Lower panel) Representative traces in the open field test. Blue point: starting position; red point: ending position. c (Left panel) Representative immunostaining showing TH-positive neurons in the SN. (Right panel) The average number of TH-positive neurons in the ST. n = 3 per group, 3 sections per mouse. d (Left panel) Representative immunostaining (upper) and western blotting (lower) showing TH-positive fibers and TH protein levels in the striatum. (Right panel) The quantification of TH-positive fibers (upper) and TH protein levels (lower) in the striatum. Immunostaining: n = 3 per group, 3 sections per mouse; western blotting: n = 3 per group. The data represent the mean ± SEM, p < 0.05 was set as the threshold for significance by one-way ANOVA followed by post hoc comparisons using Tukey’s test for multiple groups’ comparisons, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001CC BY · PubMed Central
Fig. 8 Enteric nervous system mediated the neuroprotective effects of propionate in 6-OHDA-induced PD mice. a The relative expression of FFAR3 in cortex, hippocampus, striatum, jejunum, ileum, and colon. n = 4. b Bar plot of the serum level of Glp-1 among different groups. n = 7–12. c (Left panel) Representative immunostaining showing TH-positive neurons in the SN. (Right panel) The average number of TH-positive neurons in the ST. n = 3 per group, 3 sections per mouse. d (Left panel) Representative immunostaining showing TH-positive fibers in the striatum. (Right panel) The quantification of TH-positive fibers in the striatum. Immunostaining: n = 3 per group, 3 sections per mouse. The data represent the mean ± SEM, p < 0.05 was set as the threshold for significance by one-way ANOVA followed by post hoc comparisons using Tukey’s test for multiple groups’ comparisons, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
Fig. 8 Enteric nervous system mediated the neuroprotective effects of propionate in 6-OHDA-induced PD mice. a The relative expression of FFAR3 in cortex, hippocampus, striatum, jejunum, ileum, and colon. n = 4. b Bar plot of the serum level of Glp-1 among different groups. n = 7–12. c (Left panel) Representative immunostaining showing TH-positive neurons in the SN. (Right panel) The average number of TH-positive neurons in the ST. n = 3 per group, 3 sections per mouse. d (Left panel) Representative immunostaining showing TH-positive fibers in the striatum. (Right panel) The quantification of TH-positive fibers in the striatum. Immunostaining: n = 3 per group, 3 sections per mouse. The data represent the mean ± SEM, p < 0.05 was set as the threshold for significance by one-way ANOVA followed by post hoc comparisons using Tukey’s test for multiple groups’ comparisons, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 66 · Cited by 231

Metadata

Authors
Hou, Y.-F., Shan, C., Zhuang, S.-Y., Zhuang, Q.-Q., Ghosh, A., Zhu, K.-C., Kong, X.-K., Wang, S.-M., Gong, Y.-L., Yang, Y.-Y., Tao, B., Sun, L.-H., Zhao, H.-Y., Guo, X.-Z., Wang, W.-Q., Ning, G., Gu, Y.-Y., Li, S.-T., & Liu, J.-M.
Affiliations
Shanghai Jiao Tong University (CN)
Corresponding author
  • Gu, Yan-yun
  • Li, Sheng-tian
Venue
Microbiome
Published
2021-01-31
Volume
9
Issue
1
Pages
34-34
ISSN
2049-2618 (ISSN-L)
OpenAlex
W3127844969
Cited by
231
References
66
Citations by year
2026: 23 · 2025: 53 · 2024: 55 · 2023: 50 · 2022: 29 · 2021: 19
FWCI
18.40
Type
journal article
Language
en
Open access
Licence
Locations
  • Microbiome (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (81870619, 81871064)
  • National Key Research and Development Program of China (2016YFC1201701)
  • Shanghai Committee of Science and Technology (13dz2260500)
  • Innovation Program of Shanghai Municipal Education Commission (2019-01-07-00-02-E00037)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
Keywords
Parkinson's disease, osteocalcin, gut microbiota, propionate, neuroprotection, dopaminergic neuron loss, motor impairment, 6-hydroxydopamine, Bacteroidetes, Firmicutes, FFAR3, enteric nervous system, fecal microbiota transplantation, antibiotics, microbial metabolites
MeSH terms
Gastrointestinal Microbiome, Fecal Microbiota Transplantation, Animals, Anti-Bacterial Agents, Disease Models, Animal, Infusions, Parenteral, Male, Parkinson Disease, Propionates, Osteocalcin, Oxidopamine, Disease Progression, Neuroprotective Agents, Receptors, G-Protein-Coupled, Mice, Dopaminergic Neurons

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Gut microbiota-derived propionate mediates the neuroprotective effect of osteocalcin in a mouse model of Parkinson’s disease. https://app.cochat.ai/papers/10.1186/s40168-020-00988-6
The paper
Hou, Y.-F., Shan, C., Zhuang, S.-Y., Zhuang, Q.-Q., Ghosh, A., Zhu, K.-C., Kong, X.-K., Wang, S.-M., Gong, Y.-L., Yang, Y.-Y., Tao, B., Sun, L.-H., Zhao, H.-Y., Guo, X.-Z., Wang, W.-Q., Ning, G., Gu, Y.-Y., Li, S.-T., & Liu, J.-M. (2021). Gut microbiota-derived propionate mediates the neuroprotective effect of osteocalcin in a mouse model of Parkinson’s disease. Microbiome. https://doi.org/10.1186/s40168-020-00988-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.